Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
18
08
2020
accepted:
07
01
2021
revised:
14
12
2020
pubmed:
29
1
2021
medline:
1
2
2022
entrez:
28
1
2021
Statut:
ppublish
Résumé
Late-life depression is common and often inadequately managed using existing therapies. Depression is also associated with increased markers of inflammation, suggesting a potential role for anti-inflammatory agents. ASPREE-D is a sub-study of ASPREE, a large multi-centre, population-based, double-blind, placebo-controlled trial of aspirin vs placebo in older Australian and American adults (median follow-up: 4.7 years) of whom 1879 were depressed at baseline. Participants were given 100 mg daily dose of aspirin or placebo. Depressive symptoms were assessed annually using the validated, self-rated short version of the Center for Epidemiological Studies Depression scale. There was a significant increase in depressive scores (0.6; 95% CI 0.2 to 0.9; χ
Identifiants
pubmed: 33504953
doi: 10.1038/s41380-021-01020-5
pii: 10.1038/s41380-021-01020-5
pmc: PMC8313623
mid: NIHMS1661143
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5161-5170Subventions
Organisme : NIA NIH HHS
ID : P30 AG024824
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG029824
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG062682
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.
Références
Kok RM, Reynolds CF. Management of depression in older adults: a review. JAMA. 2017;317:2114–22.
doi: 10.1001/jama.2017.5706
Sobieraj DM, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, et al. Adverse effects of pharmacologic treatments of major depression in older adults. J Am Geriatr Soc. 2019;67;1–11.
doi: 10.1111/jgs.15966
Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, Dombrowski R, et al. American Geriatrics Society 2019 updated AGS Beers Criteria®for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674–94.
Smith KJ. The association between C-reactive protein, Interleukin-6 and depression among older adults in the community: a systematic review and meta-analysis. Exp Gerontol. 2018;102:109–32.
doi: 10.1016/j.exger.2017.12.005
Berk M, Woods RL, Nelson MR, Shah RC, Reid CM, Storey E, et al. ASPREE-D: Aspirin for the Prevention of Depression in the Elderly. Int Psychogeriatr. 2016;28:1741–8.
doi: 10.1017/S104161021600079X
Köhler-Forsberg O, N. Lydholm C, Hjorthøj C, Nordentoft M, Mors O, Benros ME. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019;139:404–19.
doi: 10.1111/acps.13016
Kessing LV, Rytgaard HC, Gerds TA, Berk M, Ekstrøm CT, Andersen PK. New drug candidates for depression—a nationwide population-based study. Acta Psychiatr Scand. 2019;139:68–77.
doi: 10.1111/acps.12957
Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O’Neil A, et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med. 2013;11:1–17.
doi: 10.1186/1741-7015-11-74
Molero P, Ruiz-Estigarribia L, Lahortiga-Ramos F, Sánchez-Villegas A, Bes-Rastrollo M, Escobar-González M, et al. Use of non-steroidal anti-inflammatory drugs, aspirin and the risk of depression: the “Seguimiento Universidad de Navarra (SUN)” cohort. J Affect Disord. 2019;247:161–7.
doi: 10.1016/j.jad.2019.01.020
Wang Y, Yang F, Liu YF, Gao F, Jiang W. Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neurosci Lett. 2011;499:74–9.
doi: 10.1016/j.neulet.2011.05.035
Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE, Meyer M, et al. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry. 2018;8:27.
doi: 10.1038/s41398-017-0073-7
Sepehrmanesh Z, Fahimi H, Akasheh G, Davoudi M, Gilasi H, Ghaderi A. The effects of combined sertraline and aspirin therapy on depression severity among patients with major depressive disorder: a randomized clinical trial. Electron Physician. 2017;9:5770–7.
doi: 10.19082/57
ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36:555–64.
doi: 10.1016/j.cct.2013.09.014
Berk M, Woods RL, Nelson MR, Shah RC, Reid CM, Storey E, et al. Effect of aspirin vs placebo on the prevention of depression in older people: a randomized clinical trial. JAMA Psychiatry. 2020;77:1012–20.
doi: 10.1001/jamapsychiatry.2020.1214
Chang K-F, Weng L-J. Screening for depressive symptoms among older adults in Taiwan: cutoff of a short form of the Center for Epidemiologic Studies Depression Scale. Health (Irvine Calif). 2013;05:588–94.
Mohebbi M, Nguyen V, McNeil JJ, Woods RL, Nelson MR, Shah RC, et al. Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults. Gen Hosp Psychiatry. 2018;51:118–25.
doi: 10.1016/j.genhosppsych.2017.08.002
Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult. Arch Intern Med. 1999;159:1701.
doi: 10.1001/archinte.159.15.1701
Mohebbi M, Agustini B, Woods RL, McNeil JJ, Nelson MR, Shah RC, et al. Prevalence of depressive symptoms and its associated factors among healthy community-dwelling older adults living in Australia and the United States. Int J Geriatr Psychiatry. 2019;34:1208–16.
doi: 10.1002/gps.5119
Stocks NP, González-Chica DA, Woods RL, Lockery JE, Wolfe RSJ, Murray AM, et al. Quality of Life for 19,114 participants in the ASPREE (ASPirin in Reducing Events in the Elderly) study and their association with sociodemographic and modifiable lifestyle risk factors. Qual Life Res. 2019;28:935–46.
doi: 10.1007/s11136-018-2040-z
Cohen J. Statistical power analysis for the behavioral sciences 2nd edn. Hillsdale, NJ: Erlbaum Associates; 1988.
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N. Engl J Med. 2018;379:1509–18.
doi: 10.1056/NEJMoa1805819
McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. Effect of aspirin on disability-free survival in the healthy elderly. N. Engl J Med. 2018;379:1499–508.
doi: 10.1056/NEJMoa1800722
Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: a systematic review and meta-analysis. Brain Behav Immun. 2019;79:24–38.
doi: 10.1016/j.bbi.2019.02.021
Fields C, Drye L, Vaidya V, Lyketsos C. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry. 2012;20:505–13.
doi: 10.1097/JGP.0b013e318227f4da
Okereke OI, Reynolds CF, Mischoulon D, Chang G, Vyas CM, Cook NR, et al. Effect of long-term vitamin D3 supplementation vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. JAMA. 2020;324:471–80.
doi: 10.1001/jama.2020.10224
Sanders KM, Stuart AL, Williamson EJ, Jacka FN, Dodd S, Nicholson G, et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. Br J Psychiatry. 2011;198:357–64.
doi: 10.1192/bjp.bp.110.087544
Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. 2016;21:71–9.
doi: 10.1038/mp.2015.22
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Arch Gen Psychiatry. 2013;70:31–41.
McIntyre RS, Subramaniapillai M, Lee Y, Pan Z, Carmona NE, Shekotikhina M, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiatry. 2019;76:783–90.
doi: 10.1001/jamapsychiatry.2019.0779
Berk M, Walker AJ, Nierenberg AA. Biomarker-guided anti-inflammatory therapies: from promise to reality check. JAMA Psychiatry. 2019;76:779–80.
doi: 10.1001/jamapsychiatry.2019.0673
Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, Van Zyl LT, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy. Circulation 2003;108:939–44.
doi: 10.1161/01.CIR.0000085163.21752.0A
Handa O, Majima A, Onozawa Y, Horie H, Uehara Y, Fukui A, et al. The role of mitochondria-derived reactive oxygen species in the pathogenesis of non-steroidal anti-inflammatory drug-induced small intestinal injury. Free Radic Res. 2014;48:1095–9.
doi: 10.3109/10715762.2014.928411
Burgueño JF, Abreu MT. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat Rev Gastroenterol Hepatol. 2020;1–16. Available from: http://www.nature.com/articles/s41575-019-0261-4 .
Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry. 2010;68:140–7.
doi: 10.1016/j.biopsych.2010.03.018
Gopaldas M, Zanderigo F, Zhan S, Ogden RT, Miller JM, Rubin-Falcone H, et al. Brain serotonin transporter binding, plasma arachidonic acid and depression severity: a positron emission tomography study of major depression. J Affect Disord. 2019;257:495–503. (December 2018)
doi: 10.1016/j.jad.2019.07.035
Berk M, Mohebbi M, Dean OM, Cotton SM, Chanen AM, Dodd S, et al. Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin. BMC Med. 2020;18:16.
doi: 10.1186/s12916-019-1475-6
Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1994;10:77–84.
doi: 10.1016/S0749-3797(18)30622-6